1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

  • August 2019
  • 228 pages
  • ID: 5825155
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Hemophilia A and B - Global Drug Forecast and Market Analysis to 2028

Summary
Hemophilia A and B are rare, genetic, X-linked deficiencies in the blood clotting factors VIII (FVIII) and IX (FIX), respectively.Patients can be categorized as mild, moderate or severe depending on the percentage of circulating FVIII or FIX in their blood.

Patients can be treated either on-demand or prophylactically using plasma-derived or recombinant replacement factors, the current standard of care.

Although these therapies are effective, they are associated with a great treatment burden.There is a significant unmet need for new therapies that can reduce the great treatment burden associated with intravenous administration, the frequency of prophylactic infusions, and the risk of developing neutralizing antibodies, or inhibitors, against replacement factors.

Overall, the late-stage pipeline indicates an increase in the development of alternative coagulation promoters (ACPs) and gene therapies to further target these areas of significant unmet need.During the forecast window, Roche entered the market with the first monoclonal antibody targeting hemophilia A patients both with and without inhibitors, which addresses the unmet needs of frequency and route of administration.

Sanofi are also to exploring a non-replacement approach and will enter the market with the ribonucleic acid (RNA) therapeutic, Fitusiran (previously Alnylam’s), further ensuring cross-segment efficacy in patients both with and without inhibitors.The approval of these new products has begun to have a drastic effect on the hemophilia A and B treatment landscapes which is expected to continue through the forecast window.

During this forecast window, several pharmaceutical companies, including BioMarin, uniQure and Pfizer/Roche (Spark Therapeutics), will also be launching new gene therapies that aim to cure, or at least reduce the severity of, hemophilia A and B and diminish inhibitors. If approved, gene therapies will pose a threat to existing hemophilia therapies.

The analyst projects the global hemophilia A and B marketplace to experience a significant growth during the forecast period. The analyst valued the hemophilia A and B market at $6.9B in 2018 in the 8MM and expects the market to increase to $9.3B in 2028 at a Compound Annual Growth Rate (CAGR) of 2.9%. This growth will be driven primarily by the increasing prophylactic treatment rates among patients, the continued use of recombinant products and the uptake of non-replacement therapies in the 8MM. However, cost constraints in the 8MM are expected to limit the premium pricing opportunities for new products such as late-to-market long-acting factor concentrates and new alternative coagulation promoters, thereby limiting the size of the hemophilia market.

This model covers the market forecast for marketed and late-stage pipeline hemophilia A and B therapeutics. The base year of this model is 2018, and the forecast period is 2018-2028.

Key Questions Answered
- Which pipeline agents - replacement factors, alternative coagulation promoters and gene therapies - are the most promising and expected to launch in the 8MM?
- What are the forecasted sales of these agents and what will be their impact in the hemophilia A and B market?
- What are the main unmet needs in hemophilia A and B, and which pipeline drugs will fulfil these needs, and to what extent?
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
- Key Opinions Leader (KOL) and payer insights across the 8MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.

Key Highlights
- The hemophilia A & B market is expected to grow at a CAGR of 2.9% until 2028, reaching a global value of $9.3B.
- The analyst forecasts a marginal increase in prevalence rates across 8MM with AGR of 0.1% due to increased in prevalence rates across the US, Spain and UK.
- Gene therapies will emerge as novel treatments for hemophilia A & B during the forecast period. Particularly, BioMarin’s first-to-market gene therapy, ValRox is likely to perform exceptionally well. Additionally, Roche’s Hemlibra is anticipated to achieve blockbuster status by the end of the forecast period.
- Rising life expectancy for hemophilia patients leads to an increase in the size of the treated population.
- Expected launches of expensive new drugs such as gene therapies, continued preference for prophylactic regimens, continued patient evolution from plasma-based to recombinant therapies are other significant drivers of market.
- Limited scope for price premiums of late-to-market replacement products, high uptake of lower-priced drugs, rise in cost-consciousness and imposing market access barriers for the entry of expensive gene therapies are expected to affect market growth negatively.
- Level of unmet needs in hemophilia patients is high but is expected to decrease due to advances in treatments and the introduction of novel therapies.
- There are major market opportunities for the development of novel therapies, cheaper therapies for prophylaxis treatment, more effective treatments for hemophilia B patients with inhibitors and more therapies with convenient administration routes.

Scope
Overview of hemophilia A and B, including -
- Disease overview - etiology, pathophysiology, symptoms, prognosis and quality of life
- Epidemiology
- Disease management - diagnosis and treatment
Patient segmentation -
- Mild, Moderate, and Severe
- Hemophilia A and B with and without inhibitors
- Males and Females
- All ages, Pediatrics and Adults
Annualized hemophilia A and B therapeutics market revenue and treatment usage patterns -
- Patient shares and number of patients treated for marketed and pipeline products
- Duration of and, daily and annual cost of therapies per patient
- Product sales by usage and total sales of marketed and pipeline products

Key topics covered include -

- Competitive assessment of marketed and pipeline products including SWOTs and, clinical and commercial positioning.
- Unmet needs and opportunities including current and future level of attainment and gap analysis
- Pipeline assessment - analysis of commercial and clinical attributes of promising drugs in clinical development and comprehensive analysis of promising approaches and emerging trends in early stage development
- Analysis of the current and future players for the global hemophilia A and B market, including strength of marketed and pipeline products and trends in corporate strategy, profiles of leading companies in the hemophilia market.
- Market outlook of the 8MM including forecast, key events and, market drivers and barriers.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hemophilia A and B market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off

($10995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hemophilia A - Pipeline Review, H2 2019

Hemophilia A - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Hemophilia A - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2019, provides an overview of the Hemophilia A (Hematology ...

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2019

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle ...

Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2019

Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2019SummaryTransmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on